Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is positioned for success as they have a strong pipeline of drug candidates, with promising results for their lead assets NEO100 and NEO212. The use of POH in these treatments provides a novel approach to targeting CNS cancers, and the company's broad patent portfolio gives them a competitive advantage in the market. Despite facing financial challenges, NeOnc has a dedicated team and is working towards FDA approval, positioning themselves for future growth and potential partnerships.

Bears say

NeOnc Technologies Hldgs is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company's lead products, NEO100 and NEO212, aim to treat difficult-to-treat brain cancers and have shown promising anti-tumor activity in highly treatment-experienced patients. However, there is significant technical risk in dosing and delivery, and the company's pipeline is still in early stages with a 2031 projected market entry. Additionally, the potential safety concerns and limited reach of these drugs could limit their effectiveness in certain types of brain tumors, especially those located deep in the brain. Overall, the uncertain timeline and potential limitations on efficacy lead to a negative outlook on NeOnc Technologies Hldgs's stock.

NTHI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 4 analysts, NTHI has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.